Form NT 10-Q bluebird bio, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Form NT 10-Q bluebird bio, Inc. For: Jun 30
August 15, 2024 7:05 AM EDT
Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
The analyst comments "While the company has excelled in its ability to activate qualified treatment centers (QTCs)with over 70 centers activated in the U.S., beyond its goal of 40 to 50, the number... More
August 14, 2024 4:21 PM EDT
JPMorgan analyst Eric Joseph downgraded bluebird bio (NASDAQ: BLUE) from Overweight to Neutral.
The analyst comments "Were downgrading BLUE shares to N from OW following the 2Q results update. Of note, product sales of $16.1M missed street estimates by ~$6M (BBG consensus estimate of $22.6M; JPMe: $17.4M), implying 8 Zynteglo and 1 Skysona treated patients in the quarter. Despite the company noting steady commercial progress across the cell therapy portfolio in 2Q, FY24 commercial guidance was... More
